Fighting cancer poses major challenges for today's biotechnology. Canadian company Defence Therapeutics (DTC) has been showing great innovation and breaking new ground in recent years with its ACCUM® platform technology. Efforts are directed towards therapies in the fight against globally prevalent cancers such as lung cancer, breast cancer, and pancreatic cancer. With numerous patents and a new delivery technology, the Canadians are succeeding one hopeful step at a time. The global market for cancer therapies is estimated to grow at a CAGR of 8.4% from 2022 to 2030. Defence Therapeutics might already have a "silver bullet" in its barrel. However, various clinical phases still need to prove the encouraging results from animal trials in humans.Den vollständigen Artikel lesen ...
© 2023 researchanalyst.com (EN)